Table I.
Clinical characteristics associated with TILs.
| No. of cases | |||||
|---|---|---|---|---|---|
| Characteristics | TIL-low | TIL-medium | TIL-high | χ2 | P-value |
| Age (years) | 0.541 | 0.736 | |||
| <45 | 7 | 14 | 7 | ||
| 45–59 | 6 | 12 | 12 | ||
| ≥60 | 7 | 8 | 6 | ||
| Staging | 2.701 | 0.259 | |||
| I | 0 | 0 | 0 | ||
| II | 7 | 5 | 7 | ||
| III | 11 | 20 | 12 | ||
| IV | 3 | 9 | 6 | ||
| Menopausal state | 0.269 | 0.874 | |||
| Yes | 11 | 19 | 15 | ||
| No | 10 | 15 | 10 | ||
| HER2 | 6.597 | 0.037 | |||
| Positive | 6 | 7 | 13 | ||
| Negative | 15 | 26 | 12 | ||
| ER/PgR | 3.251 | 0.197 | |||
| Positive | 18 | 25 | 15 | ||
| Negative | 3 | 8 | 10 | ||
ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor; TIL, tumor-infiltrating lymphocytes.